Activity of alemtuzumab in patients with CD52-positive acute leukemia (Q83319101)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Activity of alemtuzumab in patients with CD52-positive acute leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Guillermo Garcia-Manero

object named as

Guillermo Garcia-Manero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Susan O'Brien

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Jorge Cortes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Michael J Keating

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

William Wierda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Raoul Tibes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Alessandra Ferrajoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Farhad Ravandi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Mary L Browning

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Stefan Faderl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

2645-2651

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Common themes in the pathogenesis of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Clinical use of rituximab in haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Non-Hodgkin lymphoma: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Alemtuzumab: a novel monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21901

1 reference

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Remission of adult acute lymphocytic leukaemia with alemtuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21901

7 January 2021

Identifiers

DOI

10.1002/CNCR.21901

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16688777%20AND%20SRC:MED&resulttype=core&format=json